Severe Hypertension and Renal Atrophy Associated with Indinavir

Open Access
Publisher Website
Google Scholar
Abstract
The addition of protease inhibitors to antiretroviral therapy has been a major advance in the treatment of HIV infection, delaying disease progression and death, and returning people to productive lives. Indinavir, one of the most widely prescribed HIV protease inhibitors, is relatively safe and well-tolerated, even though its use is associated with nephrolithiasis in ∼5% of patients [1, 2]. This adverse effect, generally presenting early in therapy, is not usually serious and resolves rapidly with drug discontinuation. We describe a case of severe hypertension and renal atrophy that developed during long-term therapy with indinavir.

This publication has 3 references indexed in Scilit: